Nuvation Bio Inc. (NYSE: NUVB) announces preliminary fourth quarter and full year 2025 financial results for IBTROZI (taletrectinib).
Total of 432 new patient starts on IBTROZI since launch in June 2025.
Preliminary IBTROZI net product revenue of approximately $15.7 million in Q4 and $24.7 million since launch.
Revenue Performance
Preliminary fourth quarter and full year 2025 IBTROZI net product revenue was $15.7 million and $24.7 million respectively.
Cash Position
Preliminary unaudited cash, cash equivalents, and marketable securities of approximately $529.2 million as of December 31, 2025.
Strategic Partnerships
Exclusive license collaboration agreement with Eisai Co., Ltd. on January 11, 2026, to develop taletrectinib for ROS1+ NSCLC treatments.
- Nuvation Bio saw significant growth in IBTROZI new patient starts in advanced ROS1+ NSCLC.
- Received a $25 million milestone payment for reimbursement price establishment in Japan.
- Maintaining a robust cash position to support ongoing investments in growth.
2025 marked a pivotal year for Nuvation Bio as it transitioned into a commercial-stage company with the successful launch of IBTROZI. The company aims to continue its growth trajectory in 2026 by expanding treatment reach and advancing its pipeline.